|
Sep 3
|
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Jul 29
|
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
|
|
May 14
|
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
|
|
May 14
|
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
|
|
Apr 25
|
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health
|
|
Apr 23
|
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
|
|
Apr 16
|
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
|
|
Apr 2
|
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
|
|
Mar 19
|
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
|
|
Dec 5
|
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
|
|
Oct 4
|
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label
|